Larry Witte

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC.

American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.